알림

NeoGenomics Inc. (NEO)

NasdaqCM: NEO · 실시간 가격 · USD

15.90

-0.26 (-1.61%)

종가 기준: Aug 18, 2026, 3:59 PM

15.90

+0.00%

애프터마켓: 7:30 PM

-1.61% (1D)

매수호가	11.52
시가총액	2.04B
매출 (ttm)	766.29M
순이익 (ttm)	-51.88M
베타	1.73
EPS (ttm)	-0.39
P/E (ttm)	n/a
선행 P/E	46.27
P/B (ttm)	2.59
P/S (ttm)	2.70
Earnings Date	Apr 29, 2025

매도호가	20.23
거래량	878,821
평균 거래량 (20일)	2,742,733
시가	16.04
전일 종가	16.16
일중 범위	15.75 - 16.30
52주 범위	5.94 - 16.92
애널리스트	Buy
목표주가	19 (19.50%)
배당	n/a
배당락일	n/a

NEO 소개

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing se...

[더 보기]

산업 Diagnostics & Research

섹터 Healthcare

IPO 일자 Mar 16, 2004

직원 수 2,500

상장 거래소 NasdaqCM

티커 NEO

웹사이트 https://www.neogenomics.com

전체 기업 정보

재무 실적

2025년 NeoGenomics의 매출은 727.33M로, 전년 660.57M 대비 10.11% 증가했습니다. 순이익은 -108.03M로, 37.22% 증가했습니다.

재무제표

애널리스트 전망

애널리스트 9명의 투자의견을 종합하면 NEO 주식의 평균 등급은 "Buy"입니다. 12개월 목표주가는 19로, 최근 주가 대비 19.5% 상승 여력입니다.

주가 전망

어닝 서프라이즈

NeoGenomics가 Jul 28, 2026에 분기 실적을 발표했습니다:

매출 $201.66M 예상치 하회 $0, 및 11.21% 전년 대비 성장.

EPS 0.05 예상치 상회 0.02, 및 66.67% 전년 대비 성장.

다음 실적 발표

NeoGenomics Inc.의 실적 발표 예정일은 Apr 29, 2025, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · StockStory

3 Stocks Under $50 with Open Questions

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some ...

1주 전 · Simply Wall St.

NeoGenomics (NEO) Is Up 8.4% After Q2 Profit Return And Raised 2026 Outlook – Has The Bull Case Changed?

In July 2026, NeoGenomics, Inc. reported second-quarter 2026 results showing revenue of US$201.66 million and net income of US$2.24 million, compared with revenue of US$181.33 million and a net loss o...

2주 전 · Zacks

NeoGenomics, Inc. (NEO) Hit a 52 Week High, Can the Run Continue?

NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

2주 전 · Simply Wall St.

NeoGenomics (NEO) Following Q2 Profit And Raised Outlook, Is Fair Value Already Priced In?

NeoGenomics (NEO) is back in focus after second quarter earnings on 28 July 2026 reported quarterly profitability, revenue of US$201.66 million, and updated full year guidance that raised revenue expe...

2주 전 · StockStory

3 Healthcare Stocks with Questionable Fundamentals

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance bu...

2 페이지 중 1

NeoGenomics Inc. (NEO)